已收录 268920 条政策
 政策提纲
  • 暂无提纲
Effects of L -arginine on preeclampsia risks and maternal and neonatal outcomes: A systematic review and meta-analysis
[摘要] Objective:  To summarize whether the supplementation of L-arginine in pregnant women helps in management of preeclampsia and its impact on maternal and neonatal outcomes. Methods:  Studies conducted from the past 17 years (1999 to 2016). were referred from database like Cochrane Central Registry of Controlled Trials (CENTRAL), Scopus, Google Scholar and PubMed. Out of 134 studies, 7 studies were included. L-arginine versus placebo was considered for quantitative analysis. Modified Cochrane data extraction form was used to collect the data. The risk of bias was assessed using Cochrane's risk of bias assessment tool in RevMan 5.4 and the summary of findings was determined using GradePro software. Results:  L-arginine showed a significant reduction of preeclampsia [odds ratio (OR) 0.38; 95% confidence interval (CI) 0.25, 0.58)]. There was a significant reduction in systolic blood pressure [mean difference (MD) -2.47; 95% CI -4.53, -0.42] and diastolic blood pressure (MD -0.97; 95% CI -3.83, 1.89). The effects of L-arginine on secondary outcomes like maternal gestational age, latency, neonatal weight, and appearance, pulse, grimace, activity, respiration (APGAR) score at 1st and 5th minute were not statistically significant. Conclusions:  L-arginine supplementation is effective in lowering systolic and diastolic blood pressure of preeclamptic patients. However, it has no noticeable effects on maternal and neonatal outcomes.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 兽医学
[关键词] L-arginine;Amino acid supplementation;Preeclampsia;Pregnancy;Arginine supplementation [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文